Skip to content Skip to footer
Subscribe Now

NEWS

Medtronic to Acquire Scientia Vascular for $550M
Shots: Medtronic has entered into a definitive agreement to acquire Scientia Vascular, expanding its neurovascular device portfolio As per the deal, Medtronic will acquire Scientia Vascular for $550M, with potential undisclosed earn-out & milestone payments post-acquisition Acquisition will integrate Scientia’s access platform with Medtronic’s neurovascular therapies to support the full procedural workflow for hemorrhagic &…
2 hours ago
Pulse Biosciences Reports Clinical Data on nPulse Vybrance System for Benign Thyroid Nodule Ablation
Shots:  Pulse Biosciences has reported clinical data from the ablation study (n=21), an extension of the initial feasibility study, to assess the outcome durability of the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules Long-term follow-up showed durable efficacy with ~74% average volume reduction in treated benign thyroid nodules at 15-22mos., continued reduction was…
20 hours ago
Agilent Technologies to Acquire Biocare Medical for $950M
Shots: Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical from investor groups led by Excellere Partners & GHO Capital Partners As per the deal, Agilent will acquire Biocare in an all-cash transaction valued at $950M, with closing anticipated by Q4’26, after which Biocare will become a part of the Agilent Life…
24 hours ago
GSK Licenses Linerixibat’s Global Rights to Alfasigma in ~$690M Deal
Shots: GSK has granted Alfasigma worldwide exclusive rights to develop, manufacture & commercialise linerixibat for cholestatic pruritus in primary biliary cholangitis As per the deal, GSK will receive $300M upfront, $100M upon FDA approval (based on PDUFA date of Mar 24, 2026), $20M upon EU & UK approval, & ~$270M in sales milestones, along with…
2 days ago
Load more